LENZ Therapeutics Launches VIZZ™ in the U.S. for the Treatment of Presbyopia

LENZ Therapeutics has announced that VIZZ™ (aceclidine ophthalmic solution, 1.44%), the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now commercially available in the United States. Product sampling to eye care professionals has begun, with broader consumer access expected by mid-Q4 2025.

U.S. Commercial Launch Underway

The launch of VIZZ marks a significant milestone in presbyopia care. LENZ has initiated nationwide sample distribution to optometrists and ophthalmologists, allowing professionals to provide early access to patients.

According to LENZ, consumer shipments through the company’s ePharmacy partner will begin in October 2025, with broad retail pharmacy availability anticipated by mid-Q4.

Eef Schimmelpennink, President and CEO of LENZ Therapeutics, commented:

“We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States. The team has been preparing for this moment for months and worked tirelessly to enable the availability of product samples and commercial product following our FDA approval. Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a category of one for the treatment of presbyopia.”

Mechanism of Action: Pupil-Selective Aceclidine

VIZZ is powered by aceclidine, a pupil-selective miotic that works by stimulating the iris sphincter muscle, resulting in a pinhole effect that enhances depth of focus. Unlike traditional miotics, VIZZ achieves this effect with minimal stimulation of the ciliary muscle, thereby reducing the risk of inducing a myopic shift.

The treatment leads to the formation of a sub-2-mm pupil, effectively improving near vision without compromising distance clarity.

CLARITY Phase 3 Trial Results

In the CLARITY Phase 3 clinical trial, VIZZ demonstrated strong efficacy:

       • 93% of participants achieved 20/40 or better near vision

       • Improvements were noted within 30 minutes of instillation

       • Effects lasted up to 10 hours

This level of improvement enabled participants to read phone screens and fine print without the need for reading glasses, addressing a major unmet need for the estimated 128 million U.S. adults living with presbyopia.